|Mr. Michael H. Tardugno||Exec. Chairman, Chief Exec. Officer and Pres||539.25k||N/A||66|
|Mr. Jeffrey W. Church CPA||CFO, Sr. VP of Corp. Strategy & IR and Corp. Sec.||354.04k||N/A||60|
|Dr. Khursheed Anwer Ph.D., M.B.A.||Chief Scientific Officer and Exec. VP||315.32k||N/A||57|
|Dr. Nicholas Borys M.D.||Chief Medical Officer and Sr. VP||381.83k||N/A||58|
|Mr. Timothy J. Tumminello CPA||Chief Accounting Officer and Controller||N/A||N/A||59|
Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The companys lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Celsion Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.